Non-Linear Mathematical Model of the Interaction between Tumor and Oncolytic Viruses

Show more

References

[1] D. H. Kirn and F. McCormick, “Replicating Viruses as Selective Cancer Therapeutics,” Molecular Medicine Today, Vol. 2, No. 12, 1996, pp. 519-527.
doi:10.1016/S1357-4310(97)81456-6

[2] K. A. Parato, D. Senger, P. A. Forsyth and J. C. Bell, “Recent Progress in the Battle between Oncolytic Viruses and Tumours,” Nature Reviews Cancer, Vol. 5, No. 12, 2005, pp. 965-976. doi:10.1038/nrc1750

[3] F. McCormick, “Cancer-Specific Viruses and the Development of ONYX-015,” Cancer Biology and Therapy, Vol. 2, No. 4, 2003, pp. S157-S160.

[4] H. Kasuya, S. Takeda, S. Nomoto and A. Nakao, “The Potential of Oncolytic Virus Therapy for Pancreatic Cancer,” Cancer Gene Therapy, Vol. 12, No. 9, 2005, pp. 725-736. doi:10.1038/sj.cgt.7700830

[5] D. Kirn, T. Hermiston and F. McCormick, “ONYX-015: Clinical Data Are Encouraging,” Nature Medicine, Vol. 4, No. 12, 1998, pp. 1341-1342. doi:10.1038/3902

[6] F. R. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randlev, A. M. Gillenwater, P. Bruso, S. B. Kaye, W. K. Hong and D. H. Kirn, “A Controlled Trial of Intratumoral ONYX-015, a SelectivelyReplicating Adenovirus, in Combination with Cisplatin and 5-Fluorouracil in Patients with Recurrent Head and Neck Cancer,” Nature Medicine, Vol. 6, No. 8, 2000, pp. 879-885. doi:10.1038/78638

[7] J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, L. Romel, B. Randlev, S. Kaye and D. Kirn, “Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients with Refractory Head and Neck Cancer,” Journal of Clinical Oncology, Vol. 19, No. 2, 2001, pp. 289-298.

[8] A. C. Shah, D. Benos, G. Y. Gillespie and J. M. Markert, “Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas,” Journal of Neurooncology, Vol. 65, No. 3, 2003, pp. 203-226.
doi:10.1023/B:NEON.0000003651.97832.6c

[9] H. L. Kaufman, G. Deraffele, J. Mitcham, D. Moroziewicz, S. M. Cohen, K. S. Hurst-Wicker, K. Cheung, D. S. Lee, J. Divito, M. Voulo, J. Donovan, K. Dolan, K. Manson, D. Panicali, E. Wang, H. Horig and F. M. Mar-incola, “Targeting the Local Tumor Microenvironment with Vaccinia Virus Expressing B7.1 for the Treatment of Melanoma,” Journal of Clinical Investigation, Vol. 115, No. 7, 2005, pp. 1903-1912. doi:10.1172/JCI24624

[10] T. Reid, R. Warren and D. Kirn, “Intravascular Adenoviral Agents in Cancer Patients: Lessons from Clinical Trials,” Cancer Gene Therapy, Vol. 9, No. 12, 2002, pp. 979-986. doi:10.1038/sj.cgt.7700539

[11] D. L. Lichtenstein, K. Toth, K. Doronin, et al., “Functions and Mechanisms of Action of the Adenovirus E3 Proteins,” International Review of Immunology, Vol. 23, 2004, pp. 75-111. doi:10.1080/08830180490265556

[12] A. Zou, I. Atencio, W. M. Huang WM, et al., “Over Expression of Adenovirus E3-11.6K Protein Induces Cell Killing by Both Caspase-Dependent and Caspase-Independent Mechanisms,” Virology, Vol. 326, 2004, pp. 240-249. doi:10.1016/j.virol.2004.06.007

[13] H. Takakuwa, F. Goshima, N. Nozawa, et al., “Oncolytic Viral Therapy Using a Spontaneously Generated Herpes Simplex Virus Type 1 Variant for Disseminated Peritoneal Tumor in Immunocompetent Mice,” Archives of Virology, Vol. 148, 2003, pp. 813-825.
doi:10.1007/s00705-002-0944-x

[14] H. Wakimoto, P. R. Johnson, D. M. Knipe, et al., “Effects of Innate Immunityon Herpes Simplex Virus and Its Abilityto Kill Tumor Cells,” Gene Therapy, Vol. 10, 2003, pp. 983-990. doi:10.1038/sj.gt.3302038

[15] K. Ikeda, T. Ichikawa, H. Wakimoto, et al., “Oncolytic Virus Therapy of Multiple Tumors in the Brain Requires Suppression of Innate and Elicited Antiviral Responses,” Nature Medicine, Vol. 5, No. 8, 1999, pp. 881-887.
doi:10.1038/11320

[16] D. Wodarz and N. Komarova, “Computational Biology of Cancer,” World Scientific Publishing Company, 2005.
http://www.worldscibooks.com/lifesci/5642.html

[17] G. P. Karev, A. S. Novozhilov and E. V. Koonin, “Mathematical Modeling of Tumor Therapy with Oncolytic Viruses: Effects of Parametric Heterogeneity on Cell Dynamics,” Biology Direct, Vol. 1, No. 30, 2006.
doi:10.1186/1745-6150-1-30

[18] S. J. Liao, “The Proposed Homotopy Analysis Technique for the Solution of Nonlinear Problems,” Shanghai Jiao Tong University, Shanghai, 1992.

[19] S. J. Liao, “Beyond Perturbation: Introduction to the Homotopy Analysis Method,” Chapman & Hall/CRC Press, Boca Raton, 2003. doi:10.1201/9780203491164

[20] S. J. Liao, “A Kind of Approximate Solution Technique Which Does Not Depend upon Small Parameters (II): An Application in Fluid Mechanics,” International Journal of Non-Linear Mechanics, Vol. 32, 1997, pp. 815-822.
doi:10.1016/S0020-7462(96)00101-1

[21] S. J. Liao, “On the Homotopy Analysis Method for Nonlinear Problems,” Applied Mathematics and Computation, Vol. 147, 2004, pp. 499-513.
doi:10.1016/S0096-3003(02)00790-7

[22] S. J. Liao and Y. Tan, “A General Approach to Obtain Series Solutions of Nonlinear Differential Equations.” Studies in Applied Mathematics, Vol. 119, 2007, pp. 297-355. doi:10.1111/j.1467-9590.2007.00387.x

[23] S. J. Liao, “Beyond Perturbation: A Review on the Basic Ideas of the Homotopy Analysis Method and Its Applications,” Advanced Mechanics, Vol. 38, No. 1, 2008, pp. 1-34.